Absence of TTF-1 Immunoreactivity Can Predict EGFR Wild-Type in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Bosdet, I. [1 ]
Young, S. S. [1 ]
Ali, R. H. [1 ]
McNeil, B. K. [1 ]
Wong, C. [1 ]
Garbutt, K. [1 ]
Karsan, A. [1 ]
Ionescu, D. N. [1 ]
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
来源：
LABORATORY INVESTIGATION | 2012年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1974
引用
收藏
页码：474A / 474A
页数：1
相关论文
共 50 条
  • [1] Absence of TTF-1 Immunoreactivity Can Predict EGFR Wild-Type in Non-Small Cell Lung Cancer (NSCLC)
    Bosdet, I.
    Young, S. S.
    Ali, R. H.
    McNeil, B. K.
    Wong, C.
    Garbutt, K.
    Karsan, A.
    Ionescu, D. N.
    [J]. MODERN PATHOLOGY, 2012, 25 : 474A - 474A
  • [2] Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC)
    Saintigny, Pierre
    Blumenschein, George R.
    Diao, Lixia
    Wang, Jing
    Coombes, Kevin
    Liu, Suyu
    Kim, Edward
    Tsao, Anne
    Herbst, Roy
    Alden, Christine
    Lee, Jack J.
    Tang, Ximing
    Stewart, David
    Kies, Merrill
    Fossella, Frank
    Tran, Hai
    Mao, Li
    Hicks, Marshall
    Erasmus, Jeremy
    Gupta, Sanjay
    Girard, Luc
    Peyton, Michael
    Davis, Suzanne
    Lippman, Scott
    Hong, Waun Ki
    Minna, John
    Wistuba, Ignacio
    Heymach, John
    [J]. CANCER RESEARCH, 2012, 72
  • [3] ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY
    Hernandez, Alba
    Calera, Lourdes
    Alvarez, Maria
    Hernando, Jorge
    Torres, Irene
    Pajares, Isabel
    Madani, Julia
    Cebollero, Ana
    Anton-Torres, Antonio
    Artal, Angel
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1017 - S1017
  • [4] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] TTF-1 and immune checkpoint therapy in non-small cell lung cancer
    Gumbleton, Matthew
    Snyder, Eric L.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 398 - 400
  • [6] A study of EGFR wild-type non-small cell lung cancer ALK genetic mutation
    Wang, Shoufeng
    Mao, Naiquan
    Zuo, Chuantian
    Pan, Hong
    Xie, Tong
    Huang, Yaoyuan
    Pan, Qi
    Wu, Junwei
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 (05) : 976 - 980
  • [7] Examination of the importance of RUNX category in EGFR wild-type non-small cell lung cancer
    Kobayakawa, Atsushi
    Takeda, Kanako
    Masuda, Tatuya
    Yanagida, Yohei
    Obi, Natsuno
    Sakuramoto, Naoya
    Hada, Asuka
    Horiuchi, Ayaka
    Takeda, Mizuho
    Sasaki, Asami
    Matsuo, Hidemasa
    Sugiyama, Hiroshi
    Adachi, Souichi
    Kamikubo, Yasuhiko
    [J]. CANCER SCIENCE, 2021, 112 : 445 - 445
  • [8] Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non-small cell lung carcinoma
    Nakra, Tripti
    Singh, Varsha
    Nambirajan, Aruna
    Malik, Prabhat Singh
    Mohan, Anant
    Jain, Deepali
    [J]. JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2021, 55 (04) : 279 - 288
  • [9] Cost of care in EGFR mutant versus wild-type non-small cell lung cancer.
    Vusqa, Urwat Til
    Asawa, Palash
    Miller, Katherine
    Sethi, Ashish
    Rodriguez, Robin Raquel
    Friday, Andrew
    Finley, Gene Grant
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
    Wang, Duo
    Zhou, Jun
    Fang, Weimin
    Huang, Cuiqing
    Chen, Zerong
    Fan, Meng
    Zhang, Ming-Rong
    Xiao, Zeyu
    Hu, Kuan
    Luo, Liangping
    [J]. BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
12345